Howard G. Welgus - Jun 4, 2024 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Role
Director
Signature
/s/ David Topper, as Attorney-in-Fact for Howard G. Welgus
Stock symbol
ARQT
Transactions as of
Jun 4, 2024
Transactions value $
-$63,286
Form type
4
Date filed
6/6/2024, 04:15 PM
Previous filing
Jun 2, 2023
Next filing
Jun 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARQT Common Stock Options Exercise $5.95K +3.54K +2.08% $1.68 174K Jun 4, 2024 Direct
transaction ARQT Common Stock Options Exercise $10.9K +6.46K +3.72% $1.68 180K Jun 4, 2024 Direct
transaction ARQT Common Stock Sale -$28.3K -3.54K -1.97% $8.00 177K Jun 4, 2024 Direct
transaction ARQT Common Stock Sale -$51.8K -6.46K -3.66% $8.01 170K Jun 4, 2024 Direct F1
holding ARQT Common Stock 25K Jun 4, 2024 By Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARQT Stock Option (right to buy) Options Exercise $0 -3.54K -38.4% $0.00 5.68K Jun 4, 2024 Common Stock 3.54K $1.68 Direct F3
transaction ARQT Stock Option (right to buy) Options Exercise $0 -6.46K -100% $0.00* 0 Jun 4, 2024 Common Stock 6.46K $1.68 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction was executed in multiple trades in prices ranging from $8.00 to $8.155, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F2 The securities are held of record by The Welgus Living Trust, of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F3 The option is fully vested.